Anti-c-myc RNAi-Based Onconanotherapeutics

Habib, Saffiya; Ariatti, Mario; Singh, Moganavelli

doi:10.3390/biomedicines8120612

Cited by 13 publications

(15 citation statements)

References 111 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liposomes were initially identified in the 1960s following the spontaneous formation of closed lipid bilayers in water [ 52 ]. It remains a popular choice for lipid-based vehicles because of its simple structure [ 53 ]. These NPs are composed of an aqueous core that encapsulates the drug or gene of choice and is enclosed in a unilamellar or multilamellar phospholipid bilayer that contains both hydrophilic and hydrophobic groups ( Figure 3 ) [ 54 ].…”

Section: Nanomedicinementioning

confidence: 99%

Lipid Nanoparticles: Promising Treatment Approach for Parkinson’s Disease

Jagaran

Singh

2022

IJMS

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease (PD), a neurodegenerative disorder, is a life-altering, debilitating disease exhibiting a severe physical, psychological, and financial burden on patients. Globally, approximately 7–10 million people are afflicted with this disease, with the number of cases estimated to increase to 12.9 million by 2040. PD is a progressive movement disorder with nonmotor symptoms, including insomnia, depression, anxiety, and anosmia. While current therapeutics are available to PD patients, this treatment remains palliative, necessitating alternative treatment approaches. A major hurdle in treating PD is the protective nature of the blood–brain barrier (BBB) and its ability to limit access to foreign molecules, including therapeutics. Drugs utilized presently are nonspecific and administered at dosages that result in numerous adverse side effects. Nanomedicine has emerged as a potential strategy for treating many diseases. From the array of nanomaterials available, lipid nanoparticles (LNPs) possess various advantages, including enhanced permeability to the brain via passive diffusion and specific and nonspecific transporters. Their bioavailability, nontoxic nature, ability to be conjugated to drugs, and targeting moieties catapult LNPs as a promising therapeutic nanocarriers for PD. While PD-related studies are limited, their potential as therapeutics is evident in their formulations as vaccines. This review is aimed at examining the roles and properties of LNPs that make them efficient therapeutic nanodelivery vehicles for the treatment of PD, including therapeutic advances made to date.

show abstract

Section: Nanomedicinementioning

confidence: 99%

Lipid Nanoparticles: Promising Treatment Approach for Parkinson’s Disease

Jagaran

Singh

2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The c-Myc gene encodes a proto-oncoprotein, a widely recognized transcription factor regulating approximately 10–15% of genes implicated in cell proliferation, differentiation, apoptosis and other processes ( Friedman et al, 2017 ; Habib et al, 2020 ), and c-Myc mutations are often associated with tumors ( Berns et al, 1997 ; Brodsky and McCracken, 1999 ; Hermeking et al, 2000 ; Morrish et al, 2003 ; Wilson et al, 2004 ). Recently, it has been reported that USP13 is co-overexpressed with c-Myc in many tumors, such as NSCLC ( Wu et al, 2019 ), cholangiocarcinoma (CAA) ( Zhou et al, 2020 ), GSCs ( Fang et al, 2017 ), and hepatocellular carcinoma (HCC) ( Huang et al, 2020 ).…”

Section: Cellular Function Of Usp13mentioning

confidence: 99%

USP13: Multiple Functions and Target Inhibition

Yang

Zhang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

As a deubiquitination (DUB) enzyme, ubiquitin-specific protease 13 (USP13) is involved in a myriad of cellular processes, such as mitochondrial energy metabolism, autophagy, DNA damage response, and endoplasmic reticulum-associated degradation (ERAD), by regulating the deubiquitination of diverse key substrate proteins. Thus, dysregulation of USP13 can give rise to the occurrence and development of plenty of diseases, in particular malignant tumors. Given its implications in the stabilization of disease-related proteins and oncology targets, considerable efforts have been committed to the discovery of inhibitors targeting USP13. Here, we summarize an overview of the recent advances of the structure, function of USP13, and its relations to diseases, as well as discovery and development of inhibitors, aiming to provide the theoretical basis for investigation of the molecular mechanism of USP13 action and further development of more potent druggable inhibitors.

show abstract

“…Unfortunately, the trial did not meet expectations of Myc knockdown or efficacy and was discontinued. For a recent review on the subject, please refer to Habib et al (2020) .…”

Section: Blocking Myc Translationmentioning

confidence: 99%

The long journey to bring a Myc inhibitor to the clinic

Whitfield¹,

Soucek

2021

Journal of Cell Biology

View full text Add to dashboard Cite

The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable.

show abstract

Anti-c-myc RNAi-Based Onconanotherapeutics

Cited by 13 publications

References 111 publications

Lipid Nanoparticles: Promising Treatment Approach for Parkinson’s Disease

Lipid Nanoparticles: Promising Treatment Approach for Parkinson’s Disease

USP13: Multiple Functions and Target Inhibition

The long journey to bring a Myc inhibitor to the clinic

Contact Info

Product

Resources

About